Provided is a nanoparticle including a water-soluble protein, a glucan and a hydrophilic active agent, the glucan being at least partially cross-linked by a metaphosphate.

Disclosed herein are partially ordered polypeptides, which include a plurality of disordered domains and a plurality of structured domains. The partially ordered polypeptides may have phase transition behavior and form aggregates at, above, or below certain temperatures. Further provided are cellular scaffolds comprised of the partially ordered polypeptides.

The present invention relates to methods, compounds, and compositions for treating viral infections, including COVID-19 viral infections. In certain embodiments, the compositions comprise: i) a remdesivir analog, ii) remdesivir or a remdesivir analog, and a surfactant, a cyclodextrin, or a combination thereof, iii) nanoparticles comprising albumin and remdesivir or remdesivir analog, iv) liposomes comprising lipids and remdesivir or remdesivir analog; and/or v) microparticles comprising PLA and/or PLGA, and remdesivir or remdesivir analog. In certain embodiments, the compositions are aqueous (e.g., for intravenous administration). In other embodiments, the compositions are nebulized or in the form of a dry powder (e.g., for inhalation by an infected subject).

Compositions for inhibiting oligonucleotide activity in vitro or in vivo to a cell that are formulated with at least one oligonucleotide encapsulated in a lipid nanoparticle, methods of making, and methods of using the same are disclosed.

A method using polyethylene glycol to prepare fibroin nano/microspheres. A fibroin solution having a mass percentage of 1-30% and a polyethylene glycol solution having a mass percentage of 10-60% are first placed in a 4-60° C. environment for 30 minutes, the fibroin protein solution and the polyethylene glycol solution are then mixed, and fibroin nano/microspheres are produced via incubation and centrifugal washing.

Disclosed herein are drug delivery molecules that comprise a ligand that targets a cell surface molecule; a membrane penetration domain; and a payload binding domain; and pharmaceutical compositions comprising the same. Also disclosed are methods of treating cancer, inhibiting the progression of cancer, preventing cancer metastasis, and delivering a therapeutic compound to the brain in a subject in need thereof, the methods comprising identifying a subject in need thereof; providing a composition comprising the drug delivery molecule as disclosed herein; and administering an effective amount of the composition to the subject.

Provided herein are methods for the treatment of melanoma comprising administration of a composition comprising nanoparticles comprising taxane and a carrier protein.

The invention refers to a nanoparticle with a diameter which is the maximum in the nanoparticle size distribution, in the range of 10-300 nm, comprising a) a calcium phosphate nanoparticle core a), b) an active ingredient coating b) on the calcium phosphate nanoparticle core a), c) a lactic acid polymer coating c) on the active ingredient coating b), d) a cationic polymer coating d) on the lactic acid polymer coating c) selected from the group of polyethylene-imines, chitosan and human lactoferrin-derived peptides with a length of 14 to 30 amino acids.

Described herein are methods, formulations and kits for treating a patient with cancer with nanoparticle complexes comprising a carrier protein, a binding agent and paclitaxel and optionally co-treated with an anti-PD-L1 antibody.

The present invention relates to compositions and methods for treating or preventing hyperglycemia and diseases associated with hyperglycemia. In certain embodiments, the composition comprises a peptide having the amino acid sequence KRSCYK wherein the peptide consists of D-amino acids is useful in treating or preventing diabetes. In some aspects, the peptide of the invention is encapsulated in a nanoparticle.